EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Comprehensive Assessment of CFTR Modulators’ Therapeutic Efficiency for N1303K Variant

Anna Efremova, Nataliya Kashirskaya iD, Stanislav Krasovskiy, Yuliya Melyanovskaya iD, Maria Krasnova, Diana Mokrousova, Nataliya Bulatenko, Elena Kondratyeva iD, Oleg Makhnach, Tatiana Bukharova iD, Rena Zinchenko iD, Sergey Kutsev und 1 weitere

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25052770 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Anna Efremova und 12 weiteren Autor:innen. Beteiligte Einrichtung: Research Centre for Medical Genetics, Moscow 115522, Russia. Hauptthemen laut MEDLINE: Cystic Fibrosis Transmembrane Conductance Regulator, Cystic Fibrosis, Aminophenols, Aminopyridines. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Ministry of Science and Higher Education of the Russian Federation, Federal State Funded Research Institution “Research Centre for Medical Genetics”.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

p.Asn1303Lys (N1303K) is a common missense variant of the CFTR gene, causing cystic fibrosis (CF). In this study, we initially evaluated the influence of CFTR modulators on the restoration of N1303K-CFTR function using intestinal organoids derived from four CF patients expressing the N1303K variant. The forskolin-induced swelling assay in organoids offered valuable insights about the beneficial effects of VX-770 + VX-661 + VX-445 (Elexacaftor + Tezacaftor + Ivacaftor, ETI) on N1303K-CFTR function restoration and about discouraging the prescription of VX-770 + VX-809 (Ivacaftor + Lumacaftor) or VX-770 + VX-661 (Ivacaftor + Tezacaftor) therapy for N1303K/class I patients. Then, a comprehensive assessment was conducted on an example of one patient with the N1303K/class I genotype to examine the ETI effect on the restoration of N1303K-CFTR function using in vitro the patient’s intestinal organoids, ex vivo the intestinal current measurements (ICM) method and assessment of the clinical status before and after targeted therapy. All obtained results are consistent with each other and have proven the effectiveness of ETI for the N1303K variant. ETI produced a significant positive effect on forskolin-induced swelling in N1303K/class I organoids indicating functional improvement of the CFTR protein; ICM demonstrated that ETI therapy restored CFTR function in the intestinal epithelium after three months of treatment, and the patient improved his clinical status and lung function, increased his body mass index (BMI) and reduced the lung pathogenic flora diversity, surprisingly without improving the sweat test results.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic Fibrosis Transmembrane Conductance RegulatorCystic FibrosisAminophenolsAminopyridinesQuinolonesHumansColforsinMutationBenzodioxoles

Stichwörter der Autor:innen

BMIFEV1N1303Kclinical statuscystic fibrosisintestinal current measurementsintestinal organoids

Substanzen

Cystic Fibrosis Transmembrane Conductance RegulatorivacaftorColforsinlumacaftorBenzodioxolesCFTR protein, humanAminophenolsAminopyridinesQuinolones

Autor:innen und Institutionen

  • Research Centre for Medical Genetics, Moscow 115522, Russia.
  • Moscow Regional Research and Clinical Institute ("MONIKI"), Moscow 129110, Russia.
  • Pulmonology Scientific Research Institute under Federal Medical and Biological Agency of Russian Federation, Moscow 115682, Russia.

ORCID-Profile: Nataliya Kashirskaya, Yuliya Melyanovskaya, Elena Kondratyeva, Tatiana Bukharova, Rena Zinchenko

Förderung

  • The Ministry of Science and Higher Education of the Russian Federation
  • Federal State Funded Research Institution “Research Centre for Medical Genetics”

Zitieren

APA

Efremova, A., Kashirskaya, N., Krasovskiy, S., Melyanovskaya, Y., Krasnova, M., Mokrousova, D., Bulatenko, N., Kondratyeva, E., Makhnach, O., Bukharova, T., Zinchenko, R., Kutsev, S., & Goldshtein, D. (2024). Comprehensive Assessment of CFTR Modulators’ Therapeutic Efficiency for N1303K Variant. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25052770

Vancouver

Efremova A, Kashirskaya N, Krasovskiy S, Melyanovskaya Y, Krasnova M, Mokrousova D, et al. Comprehensive Assessment of CFTR Modulators’ Therapeutic Efficiency for N1303K Variant. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25052770

BibTeX
@article{Efremova2024,
  author = {Efremova, Anna and Kashirskaya, Nataliya and Krasovskiy, Stanislav and Melyanovskaya, Yuliya and Krasnova, Maria and Mokrousova, Diana and Bulatenko, Nataliya and Kondratyeva, Elena and Makhnach, Oleg and Bukharova, Tatiana and Zinchenko, Rena and Kutsev, Sergey and Goldshtein, Dmitry},
  title = {Comprehensive Assessment of CFTR Modulators’ Therapeutic Efficiency for N1303K Variant},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25052770}
}
Kostenlos starten →